Back to results
US 2026/0092281 A1Published application
Methods for treatment of anemia
AssigneeDexcel Pharma Technologies Ltd.
InventorsNadav Marbach-Bar, Elena Feinstein, Noa Madar-Balakirski
Life of this patent
Estimating the term…
Abstract
Provided herein are nucleic acids and compositions thereof for inhibiting expression of transferrin receptor 2 (TFR2). Also described are methods for treatment of TFR2-associated diseases, such as anemia, with the disclosed nucleic acids.
Claims13
A method for treating a HAMP-related anemia, comprising:
- administering to a subject in need thereof, an effective amount of a double-stranded nucleic acid comprising a sense strand and an antisense strand, wherein the sense strand comprises a sense strand sequence comprising:
- 5′-(C3)csgsguCfaUfAfCfugucgguuaa 3′ (SEQ ID NO:
- 308) and has three or four GalNAc moieties covalently attached to the 3′ end,
- wherein the antisense strand comprises an antisense strand sequence comprising:
- 5′-(vinu)sUfsaacCf(3dG)AfCfaguaUfgAfccgsusc-3′ (SEQ ID NO:
- 293) or 5′-(vinu)sUfsaacCf(3dG)aCfaguaUfgAfccgsusc-3′ (SEQ ID NO:
- 297),
- wherein a lowercase letter indicates a 2′-O-Methyl (2′-OMe) modified RNA nucleotide, an uppercase letter followed by f indicates a 2′-Fluoro (2′-F) modified RNA nucleotide, (C3) indicates a propanol or C3 alkyl moiety connected to the 5′ end of the strand via a phosphodiester linkage, s indicates a phosphorothioate linkage between adjacent nucleotides, (vinu) indicates a 5′ vinylphosphonate 2′-OMe RNA U nucleotide, and (3dG) indicates a G nucleotide in which ribose has H at the 3′ position, and is connected via a 2′-5′ bridge to a nucleotide following the G nucleotide,
- thereby treating the anemia.
6 more elements
Dependencies are inferred from the claim text.